본문 바로가기

Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널
대한췌담도학회지23(3) · pp.108 · 2018
피인용
KCI 0
ISSN
1976-3573

저자

  1. 김도영제1저자Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
  2. 최영진Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
  3. 설영미Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
  4. 김효정교신저자Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital

초록

Background/Aims: This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection. Methods: We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012. Results: Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012). Conclusions: Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy.

키워드

Pancreatic cancerChemotherapyChemoradiotherapyAdjuvant

식별자

KCI
ART002371603